Effect of procetofen on apolipoprotein A I and B concentrations in hyperlipoproteinemia

Thirty-three hyperlipoproteinemic patients were subjected to therapy with procetofen (300-600 mg daily) for 6 months in a placebo-controlled study. Lipoprotein changes based on cholesterol fractions have been reported previously. This report shows that procetofen increase Apo A I only slightly. Apoprotein B decreased by 16% and the ratio of Apo A I to Apo B was increased by 31%. In addition, procetofen induces changes in HDL composition: the relative amount of cholesterol is increased, which may reflect more efficient efflux of cholesterol from the tissues.